Featured tickers: $ABBV $ARNA $AVNR $BLUE $BMRN $BMY $CNAT $DVAX $FLML $FMI $FOLD $FPRX $GALE $GILD $GSK $IPH.PA $JUNO $KITE $MGNX $OXYS $NPSP $QURE $RNA $SRPT $TKMR $VYRX
WOZA!! RT @adamfeuerstein: $BMRN buying $RNA for $17.75 per share. $680M deal
— Bio Stocks™ (@BioStocks) November 24, 2014
@zwerp2000 The important thing for $SRPT today is that someone with a lot of experience thinks exon skipping works. Let's leave it at that.
— Brad Loncar (@bradloncar) November 24, 2014
Sold rna @19...52%
— Randy (@lipscrl) November 24, 2014
@Bio_Tech_Boss It is going to be hard for $GILD to get traction until $ABBV pricing overhang removed.
— David Sobek (@dsobek) November 25, 2014
$FPRX is getting $30 million up front for this, and $BMY will pay for the cost of the study.
— Brad Loncar (@bradloncar) November 24, 2014
Been awhile since IPH.PA gets halted for running 10%+
— Zack (@BioTerp) November 24, 2014
i <3 $MGNX
— Don Shimoda (@zDonShimoda) November 24, 2014
Sold $fold 7.77 from 6.70.
— Festo (@Festo50) November 24, 2014
$CNAT having a good day. ACLF data coming soon?
— David Sobek (@dsobek) November 24, 2014
@bradloncar Hmmm. Becoming something of a habit, isn’t it?
— Adam Feuerstein (@adamfeuerstein) November 24, 2014
cc: @BioDueDiligence If this isnt deemed worthy of the wkly biotweet or whatever,I'll go long $GALE (w/ conditions) https://t.co/3iLW7TXbot
— Chet Stedman (@ChetStedman5) November 25, 2014
RBC raises $bmrn PT from $87 to $103.
— Joe (@Drchik23) November 25, 2014
There are 1000 $RTRX shares in the #zzporte portfolio btw, so by now we might actually own more shares than its former CEO ;)
— V.S. Schulz (@portefeuillefun) November 25, 2014
Sign o the times: #Google News no longer ranks #Ebola in top 20 search items, and even within the health category only Italy & US Ebola news
— Laurie Garrett (@Laurie_Garrett) November 25, 2014
Short Covering Could be Next Catalyst for Health Care ETFs | ETF Trends http://t.co/cdNvg7uU2C $XBI $IBB $XLV $FBT $ PJP $IHF $GILD $BMY
— Emory Redd (@Emory_R) November 25, 2014
According to 538 graphic. NO LIVES SAVED with PSA. None. never. The graphic is so wrong on every stat its below me to comment @cragcrest
— daviesbj (@daviesbj) November 26, 2014
$BMY complete response letter for daclatasvir $GILD
— zach (@zbiotech) November 26, 2014
@bradloncar @BioDueDiligence $FMI price then was HIGHER than now (in the $24-26 range): http://t.co/zGtDu0SIFb
— Roy Friedman (@DewDiligence) November 26, 2014
$QURE Glybera -> First #GeneTherapy drug sets a million-euro price record. http://t.co/lN00xNVjPC @adamfeuerstein @ldtimmerman @JohnCFierce
— Andy Biotech (@AndyBiotech) November 26, 2014
There ‘ya go $BLUE, you have your gene therapy price comp now. Call it $1 million per patient.
— Adam Feuerstein (@adamfeuerstein) November 26, 2014
$AVNR tapping on $15 before the likely PR of a CRL? Sometimes, you just never know lol
— Brice Foose (@PharmDFoose) November 26, 2014
Re $AEMD and today’s PR claiming shipment of ebola blood filters — Nebraska Medical Ctr spox tells me devices sent to them unsolicited!
— Adam Feuerstein (@adamfeuerstein) November 26, 2014
The $IBB $XBI & $QQQ printing New 52W high & outperforming the $SPY & $IWM
— Joe (@GantosJ) November 26, 2014
$KITE files $138M secondary offering through Jefferies, Credit Suisse and Cowen
— Ian Estepan (@ianestepan) November 26, 2014
$KITE $138M. Talked about it this morning. A good offering by good company that will put money to good use. #cancer #CART Happy Thanksgiving
— David Maizenberg (@biologypartners) November 26, 2014
Well the worst kept secret in biotech is now out. $KITE
— Brad Loncar (@bradloncar) November 26, 2014
Wow, bad news for $OXYS, merger agreement with Estill Medical terminated (no reason given) >> http://t.co/uZajzBO3Ws
— Jason Napodano, CFA (@JNapodano) November 26, 2014
My feed is a flood of shelfs, ATMS, resignations, terminations, and subpoenas. I feel like I should get a bowl of popcorn to watch this.
— Andrew Colburn (@AceOfSpades2007) November 26, 2014
$TKMR $150m shelf
— Shane Blackmon (@shaneblackmon) November 26, 2014
Today was way more fun than I expected.
— Adam Feuerstein (@adamfeuerstein) November 26, 2014
Belviq commercial on the TV on Thanksgiving - seems fitting $ARNA
— Red Acre Investments (@redacre) November 27, 2014
Cool(short) piece on NBC Football about CAR-T in a patient friends with Russell Wilson http://t.co/zWE1U2YziV $JUNO
— Patrick (@chasingthealpha) November 28, 2014
Hahaha $GSK returns $DVAX, & going by their record in $RNA, $FOLD, one must be buying $DVAX LT
— Ponty (@pbmech) November 28, 2014
Nice little deal by $flml. Should reduce costs. Also opens up some optionality w potential royalty based licensing deals.
— NathanAaron (@NathanAhron) November 28, 2014